Celyad Email Format
Biotechnology ResearchWallonia, Belgium11-50 Employees
Celyad Oncology is a Belgian biotechnology company headquartered in Mont-Saint-Guibert, Wallonia, focused on developing CAR T-cell therapies and leveraging its intellectual property. It operates within the biotechnology research sector and seeks to advance its programs through continued research and development. As a relatively small to mid-sized firm, it concentrates on innovative cellular therapies derived from its IP. In 2023, Fortress Investment Group affiliates crossed the 25% ownership threshold, indicating substantial ownership of the company's shares. That same year, the company announced the voluntary delisting of its American Depositary Shares from Nasdaq and continued listing on Euronext Brussels.